Alam, MarziaAfsana, Nourin2022-09-112022-09-1120212021-09ID 16346053http://hdl.handle.net/10361/17186Cataloged from PDF version of thesis report.Includes bibliographical references (pages 31-46).This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.One of the most remarkable health problems we have faced since the World War II is the COVID-19 outbreak. This review article discusses insights from basic science as well as clinical perspectives on COVID-19 disease with a specific concern on Parkinson’s disease (PD). Patients with COVID-19 have compromised immunity, especially in an aged population suffering from PD. The 1st report on the relationship between COVID-19 and PD comes from the research on antibodies against four antigens of COVID-19 in Cerebrospinal Fluid (CSF) of normal controls compared to patients with neurological illnesses, especially PD. Unfortunately, identification of COVID-19 is difficult in PD patients because PD is often preceded by anosmia, which is a common feature of COVID-19. Presently, no disease-modifying treatment is available for PD. But for temporary relief, the treatment is composed of dopaminergic drugs like levodopa and PD patients with COVID-19 are treated with favipiravir, amantadine etc. where amantadine was the first FDA-approved medicine in the United States that indicates dual function in the treatment of both diseases. This review also discusses the COVID-19 negative impact on PD patients due to lockdown/isolation. To conclude, this review is mainly focused on the COVID-19 and PD relationship, consequences of PD patients infected with COVID-19, treatment options and COVID-19 impact on PD patients.46 pagesenBrac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.Covid-19Parkinson's diseaseAntibodiesAnosmiaAmantadineLockdownParkinson's diseaseCOVID-19 (Disease)--TreatmentThesis